Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.
暂无分享，去创建一个
A. Hauschild | D. Schadendorf | R. Dummer | R. Plummer | J. Kirkwood | J. Schachter | M. Mandalà | V. Chiarion-Sileni | R. Kefford | G. Long | C. Robert | A. Haydon | K. Dasgupta | L. Mortier | B. Mookerjee | M. Nyakas | M. Santinami | V. Atkinson | C. Dutriaux | T. Lesimple | S. Manson | R. Koruth | J. Larkin | Kohinoor Dasgupta